Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix

A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi's Labs

Related Keywords

Prabhudas Lilladher , ,Nuvama Institutional Equities ,Kotak Institutional Equities ,Incred Equities ,Active Pharmaceutical Ingredients ,Results ,Divis Laboratories ,Ivis Labs Q2 ,Ivis Labs Q2 Results ,Divis Labs Q2 Preview ,Divis Labs Q2 Earnings ,Ivis Labs Q2 Earnings Updates ,Ivis Labs Q2 Results Updates ,